456 related articles for article (PubMed ID: 2642814)
1. The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use.
Spellacy WN; Ellingson AB; Tsibris JC
Fertil Steril; 1989 Jan; 51(1):71-4. PubMed ID: 2642814
[TBL] [Abstract][Full Text] [Related]
2. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial.
Notelovitz M; Kitchens CS; Khan FY
Am J Obstet Gynecol; 1992 Nov; 167(5):1255-61. PubMed ID: 1442974
[TBL] [Abstract][Full Text] [Related]
3. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease.
Godsland IF; Crook D; Devenport M; Wynn V
Contraception; 1995 Sep; 52(3):143-9. PubMed ID: 7587185
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a new triphasic oral contraceptive in private practice.
Ellsworth HS; Ayerst RI; Harris JW; Stone RA; Anderson AE; Jones TL; Curtis MK
Contraception; 1986 Nov; 34(5):435-42. PubMed ID: 3102161
[TBL] [Abstract][Full Text] [Related]
5. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
[TBL] [Abstract][Full Text] [Related]
6. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.
Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V
N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499
[TBL] [Abstract][Full Text] [Related]
7. Insulin resistance, secretion, and metabolism in users of oral contraceptives.
Godsland IF; Walton C; Felton C; Proudler A; Patel A; Wynn V
J Clin Endocrinol Metab; 1992 Jan; 74(1):64-70. PubMed ID: 1530790
[TBL] [Abstract][Full Text] [Related]
8. [Influence of progestins on adverse effects of oral contraceptives].
Wynn V
Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210
[TBL] [Abstract][Full Text] [Related]
9. Lack of metabolic effects of a triphasic formulation containing norethindrone in normal women studied prospectively.
Toth EL; Ryan EA
Contraception; 1988 Jun; 37(6):549-54. PubMed ID: 3293908
[TBL] [Abstract][Full Text] [Related]
10. Glucose and insulin levels after six months of treatment with a triphasic oral contraceptive containing ethinyl estradiol and norethindrone.
Spellacy WN; Ellingson AB; Tsibris JC
J Reprod Med; 1989 Aug; 34(8):540-2. PubMed ID: 2681750
[TBL] [Abstract][Full Text] [Related]
11. Carbohydrate metabolism during treatment with estrogen, progestogen, and low-dose oral contraceptives.
Spellacy WN
Am J Obstet Gynecol; 1982 Mar; 142(6 Pt 2):732-4. PubMed ID: 7039318
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the clinical performance of three triphasic oral contraceptives: a multicenter, randomized comparative trial.
Schilling LH; Bolding OT; Chenault CB; Chong AP; Fleury F; Forrest K; Glick HI; Hasson HM; Heil CG; London RS
Am J Obstet Gynecol; 1989 May; 160(5 Pt 2):1264-8. PubMed ID: 2655451
[TBL] [Abstract][Full Text] [Related]
13. Plasma glucose and insulin levels in women using a levonorgestrel-containing triphasic oral contraceptive for three months.
Spellacy WN; Ellingson AB; Kotlik A; Tsibris JC
Contraception; 1988 Jul; 38(1):27-35. PubMed ID: 3139358
[TBL] [Abstract][Full Text] [Related]
14. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring.
Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST
Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404
[TBL] [Abstract][Full Text] [Related]
15. The effect of triphasic and biphasic oral contraceptive preparations on HDL-cholesterol and LDL-cholesterol in young women.
Percival-Smith RK; Morrison BJ; Sizto R; Abercrombie B
Contraception; 1987 Feb; 35(2):179-87. PubMed ID: 3595143
[TBL] [Abstract][Full Text] [Related]
16. Effects of desogestrel on carbohydrate metabolism.
Shoupe D
Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 2):1041-7. PubMed ID: 8447358
[TBL] [Abstract][Full Text] [Related]
17. Oral contraceptives and coronary heart disease: modulation of glucose tolerance and plasma lipid risk factors by progestins.
Crook D; Godsland IF; Wynn V
Am J Obstet Gynecol; 1988 Jun; 158(6 Pt 2):1612-20. PubMed ID: 3287933
[TBL] [Abstract][Full Text] [Related]
18. Three triphasic oral contraceptives now available in U.S.
Contracept Technol Update; 1985 Jan; 6(1):1-2, 4. PubMed ID: 12279912
[TBL] [Abstract][Full Text] [Related]
19. Prospective study of carbohydrate metabolism in women using a triphasic oral contraceptive containing norethindrone and ethinyl estradiol for 3 months.
Spellacy WN; Ellingson AB; Kotlik A; Tsibris JC
Am J Obstet Gynecol; 1988 Oct; 159(4):877-9. PubMed ID: 3052079
[TBL] [Abstract][Full Text] [Related]
20. Six-month carbohydrate metabolism studies in women using oral contraceptives containing gestodene and ethinyl estradiol.
Spellacy WN; Tsibris JC; Hunter-Bonner DL; Smalling S; Chez RA; Angel JL; O'Brien WF
Contraception; 1992 Jun; 45(6):533-9. PubMed ID: 1617962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]